関連する実験動画
Updated: May 1, 2026

06:37
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
8.0K
抗単細胞化学誘導タンパク質-1遺伝子療法は,実験的な心筋梗塞後の左心室リモデリングと不全を弱める
Shunji Hayashidani1, Hiroyuki Tsutsui, Tetsuya Shiomi
1Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Circulation
|October 1, 2003
まとめ
モノサイト化学吸引タンパク質-1 (MCP-1) の活性化により,心筋梗塞 (MI) の後の心不全が悪化する. 遺伝子治療でMCP-1を阻害すると,MIのマウスでは生存率が向上し,心臓の改造が減少しました.
科学分野:
- 心血管生物学 心血管生物学
- 分子医学は分子医学である.
- 再生医学は,再生医療である.
背景:
- 単細胞化学吸引タンパク質-1 (MCP-1) の発現は,心不全の患者で上昇しています.
- 心筋梗塞 (MI) 以後の心不全の病理生理学におけるMCP-1の役割は完全に理解されていません.
研究 の 目的:
- 心臓発作後の心臓におけるMCP-1レベルを調査する.
- MCP-1を阻害することで,左心室 (LV) の改造と衰えを防ぐことができるかどうかを判断する.
主な方法:
- マウスは冠動脈連動によってMI誘導を受けた.
- MCP-1シグナリングは,骨格筋に届くヒトMCP-1遺伝子のN末端デレーション変異体による遺伝子療法を用いてブロックされました.
- LV機能,リモデリング,線維症,マクロファージの浸透,および遺伝子発現は,MIの4週間後に評価されました.
主要な成果:
- MCP-1 mRNAレベルは,不発症のLVのMI後の患者で有意に上昇した.
- MCP-1封鎖は生存率を向上させ (61%対87%) LVの膨張,収縮機能障害,インタースティシャル線維症を弱めた.
- 治療を受けたMIマウスでは,マクロファージ募集の減少とTNF-αとTGF-βの発現の抑制が観察されました.
結論:
- MCP-1のアクティベーションは,心筋梗塞の後のLVの改造と故障の主要な要因です.
- 抗MCP-1遺伝子療法は,心筋梗塞後の心不全を予防するための有望な戦略です.
さらに関連する動画
関連する概念動画
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy IV: Restrictive Cardiomyopathy
952
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952
Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

